BioInvent reports net revenues of SEK 63.1M for January – June 2010 period
BioInvent reports net revenues of SEK 63.1M for January – June 2010 period
BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company’s partner, ThromboGenics, will now prioritise securing a development …
Read more on News-Medical-Net
Categories: Metastatic Breast Cancer Tags: 2010, 63.1M, BioInvent, January., June, period., Reports, Revenues
Reportlinker Adds Commercial Insight: Top 20 Oncology Therapy Brands in Australia Revenues of targeted therapies soar …
Reportlinker Adds Commercial Insight: Top 20 Oncology Therapy Brands in Australia Revenues of targeted therapies soar …
Reportlinker.com announces that a new market research report is available in its catalogue:
Read more on PR Newswire via Yahoo! Finance
Categories: Breast Cancer Research Tags: adds, Australia, Brands, Commercial, Insight, Oncology, Reportlinker, Revenues, soar, Targeted, Therapies, Therapy
SenoRx Reports Record Revenues and Strong Gross Margin for Fourth Quarter and Fiscal Year 2009 With Continuing …
SenoRx Reports Record Revenues and Strong Gross Margin for Fourth Quarter and Fiscal Year 2009 With Continuing …
IRVINE, Calif. — SenoRx, Inc. today reported financial results for its fourth quarter and fiscal year 2009. For the quarter ended December 31, 2009, SenoRx reported record quarterly revenues of $15.5 million, an increase of 14.2 percent compared with $13.6 million in the fourth quarter a year ago.
Read more on GlobeNewswire via Yahoo! Finance